Could become the largest deal in the biopharmaceutical industry in recent years! Sanofi (SNY.US) is preparing a blockbuster acquisition, and Insmed (INSM.US) shares surged more than 20% in response!

date
06:58 20/11/2026
avatar
GMT Eight
According to people familiar with the matter, Sanofi is evaluating the possibility of acquiring U.S. drugmaker Insmed. With a new chief executive officer at the helm, the French pharmaceutical company is actively looking for its next blockbuster drug.
According to people familiar with the matter, Sanofi (SNY.US) is evaluating the possibility of acquiring U.S. drugmaker Insmed (INSM.US). With a new chief executive officer at the helm, the French pharmaceutical company is actively searching for its next blockbuster drug. The people said Sanofi is working with advisers to study a potential deal to acquire Insmed, which focuses on treatments for respiratory diseases. If a deal is ultimately reached, it could become the largest M&A transaction in the global biopharmaceutical industry since Pfizer Inc. (PFE.US) acquired Seagen for US$43 billion in late 2023. The people added that discussions are still ongoing and any deal could still take weeks to finalize. They noted that Sanofi's acquisition interest does not mean a deal will definitely be reached, and other bidders could also emerge. Boosted by the news, Insmed rose 20.58% in U.S. trading on Thursday, after rising more than 23% at one point during the session; Sanofi fell more than 2%. Seeking a blockbuster drug Large pharmaceutical companies are exploring various avenues to replenish their product portfolios with new, high-margin therapies. Sanofi investors have been waiting for the company to make a major acquisition, targeting a business with drugs in late-stage development. Such deals are crucial to offsetting potential sales losses after its best-selling skin and asthma drug Dupixent loses patent protection. Insmed currently has two approved respiratory disease treatments on the market. Among them, Brinsupri is used to treat non-cystic fibrosis bronchiectasis, while Arikayce is used to treat refractory Mycobacterium avium complex lung disease. Last month, Insmed's shares received a boost after the company raised the lower end of its 2026 revenue guidance for the two drugs. Insmed noted that third-quarter revenue rose 268% year over year to US$524.4 million. Insmed is also developing early-stage therapies for other respiratory diseases, while building a presence in immunology, inflammation and neurological diseases. BMO Capital Markets biotechnology analysts Conor MacKay and Evan David Seigerman wrote in a report on Thursday: "The strategic fit between the two companies is obvious, and the deal would give Sanofi an opportunity to leverage its existing commercial infrastructure to help Insmed launch Brinsupri." On the third-quarter earnings call held last month, Sanofi Chief Executive Officer Beln Garijo said the company will use M&A as a means of driving growth. Earlier this year, Beln Garijo took over as CEO. Her predecessor, Paul Hudson, was removed after a costly R&D investment failed to deliver expected results. Beln Garijo, who previously headed Germany's Merck KGaA, now faces pressure to find the next blockbuster drug for the French pharmaceutical company. "Actionable and digestible" Bloomberg Intelligence analysts John Murphy and Aude Gerspacher wrote in October: "Beln Garijo has just taken over, but the challenges facing the pharmaceutical company remain unchangeddriving a leap-forward transformation of its long-underperforming R&D division and finding new sources of growth to support the Dupixent business." Sanofi has said that rare diseases will be a key focus area for the company as it looks ahead to business development after Dupixent's patent expires. The company has also signaled to the market that it may need to acquire drugs in late-stage development or even already commercialized. Such deals themselves often imply a much larger scale. Michael Leuchten, head of the European pharmaceuticals and biotechnology research team at Jefferies Financial Group Inc., said in a report that although the potential Insmed deal is "quite large for Sanofi on paper," "the deal is actionable and digestible, and from a strategic direction perspective, it appears to align with management's previous goals." Larger-scale deals Sanofi has the financial strength to carry out large-scale acquisitions. Last year, the company sold a controlling stake in its consumer healthcare unit Opella to private equity firm Clayton, Dubilier & Rice, a transaction that brought Sanofi about EUR10 billion in net cash proceeds. When Sanofi reported results last month, Chief Financial Officer Franois-Xavier Roger said the company will pursue deals significantly larger than before in the future. Franois-Xavier Roger said in an interview with reporters: "The transaction amount involved this time will exceed the scale we have sought in the past." Since taking over, Beln Garijo has halted development programs for several drugs she deemed to have poor prospects and replaced R&D head Houman Ashrafian with former Roche executive Paulo Fontoura. The company is also focused on accelerating its own drug development process, planning to launch up to 15 first-in-human clinical trials each year. Several of Sanofi's clinical trial results have been disappointing, including an experimental drug for atopic dermatitis, amlitelimab, and a drug for a rare autoimmune disease. The pharmaceutical company is expected to announce an update on its strategic priorities before the end of this year.